A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
133actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-27 | actual | When the study began enrolling |
| Primary completion | 2025-06-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-01 | actual | The whole study's end, after follow-up |
| First posted | 2024-06-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
Interventions
- Drug: NNC0487-0111 (formulation D)
- Drug: NNC0487-0111 (formulation C)
Primary outcome
what the primary-completion date above is the date OFPhase A: The area under the NNC0487-0111 plasma concentration-time curve during a dosing interval at steady state
measured From pre-dose to after dosing on days 21, 42, 63, 84, 105 and 126
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed